Abstract: Ovarian cancer is one of the common gynecologic malignant tumors. The development of it and the metastases of tumor cells need new blood vessels. Therefore, by inhibiting tumor angiogenesis is one of effective ways to treat ovarian cancer. The main antiangiogenic agents included vascular endothelial growth factor inhibitor （such as Bevacizumab）, tyrosine kinase inhibitors （such as Sorafenib, Pazopanib and Cediranib）, and angiogenin inhibitor （such as Trebananib）. The combination of antiangiogenic targeted agents with chemotherapy has been shown to benefit patients with platinum-sensitive or platinum-resistant recurrent ovarian cancer by lots of phase Ⅱ and Ⅲ clinical trials. Meanwhile, combination with chemotherapy provided a clinically meaningful prolongation in progression-free survival. This paper reviewed clinical research status and the latest development with the combination of different antiangiogenic targeted agents and chemotherapy in patients with recurrent ovarian cancer.

Key words: Ovarian neoplasms, Antineoplastic combined chemotherapy protocols, Antiangiogenic agents, Bevacizumab, Cediranib, Recurrence ovarian cancer